Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus.

Pharmacogenomics - 1 Nov 2010

Swen Jesse J, Wessels Judith A M, Krabben Annemarie, Assendelft Willem J J, Guchelaar Henk-Jan

Abstract excerpt

AIMS: Sulfonylureas are mainly metabolized by the enzyme CYP2C9. Two allelic variants, CYP2C9*2 and CYP2C9*3, result in decreased metabolic capacity and have been associated with elevated sulfonylurea serum levels. However, most of the available data originates from pharmacokinetic analyses performed in healthy individuals. In this study, the effect of CYP2C9*2 and CYP2C9*3 alleles on prescribed dose and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hypoglycemic Agents

Share to Medical Records

Share to Netherlands

Share to Primary Health Care

Share to Saliva

Share to Sulfonylurea Compounds

Source

Identifiers

PMID: 21121772
DOI: 10.2217/pgs.10.121

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus.PMID 21121772Read ↗

Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.Semantic proximity Read ↗

Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study.Semantic proximity Read ↗

CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects.Semantic proximity Read ↗

Genetic risk factors for type 2 diabetes mellitus and response to sulfonylurea treatment.Semantic proximity Read ↗

Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.Semantic proximity Read ↗

Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients.Semantic proximity Read ↗

Possible approaches to CYP2C9-guided prescription of sulfonylureas in Russia.Semantic proximity Read ↗

Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects.Semantic proximity Read ↗

Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.Semantic proximity Read ↗

Association Between the CYP2C9 Genotype and Hypoglycemia Among Patients With Type 2 Diabetes Receiving Sulfonylurea Treatment: A Meta-analysis.Semantic proximity Read ↗

Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia.Semantic proximity Read ↗

Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.